Study participants (n = 146; 101 males, 45 females) were enrolled in a 16 - week randomized clinical trial
comparing naltrexone with placebo treatment.
Not exact matches
The decision whether or not to continue
naltrexone treatment for a woman already using
naltrexone before pregnancy should involve a careful discussion with the patient that
compares the limited safety data versus the potential risk of relapse with treatment discontinuation.
The results were promising — almost 90 % of the addicted persons who received the
naltrexone shot remained abstinent during the test period,
compared to just over 60 % of the control group.